z-logo
Premium
A novel Cre recombinase reporter mouse strain facilitates selective and efficient infection of primary immune cells with adenoviral vectors
Author(s) -
Heger Klaus,
Kober Maike,
Rieß David,
Drees Christoph,
Vries Ingrid,
Bertossi Arianna,
Roers Axel,
Sixt Michael,
SchmidtSupprian Marc
Publication year - 2015
Publication title -
european journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.272
H-Index - 201
eISSN - 1521-4141
pISSN - 0014-2980
DOI - 10.1002/eji.201545457
Subject(s) - biology , cre recombinase , immune system , vector (molecular biology) , strain (injury) , virology , primary (astronomy) , viral vector , recombinase , microbiology and biotechnology , immunology , genetics , recombination , transgene , recombinant dna , gene , genetically modified mouse , physics , anatomy , astronomy
Replication‐deficient recombinant adenoviruses are potent vectors for the efficient transient expression of exogenous genes in resting immune cells. However, most leukocytes are refractory to efficient adenoviral transduction as they lack expression of the coxsackie/adenovirus receptor (CAR). To circumvent this obstacle, we generated the R26/CAG‐CARΔ1 StopF (where R26 is ROSA26 and CAG is CMV early enhancer/chicken β actin promoter) knock‐in mouse line. This strain allows monitoring of in situ Cre recombinase activity through expression of CARΔ1. Simultaneously, CARΔ1 expression permits selective and highly efficient adenoviral transduction of immune cell populations, such as mast cells or T cells, directly ex vivo in bulk cultures without prior cell purification or activation. Furthermore, we show that CARΔ1 expression dramatically improves adenoviral infection of in vitro differentiated conventional and plasmacytoid dendritic cells (DCs), basophils, mast cells, as well as Hoxb8‐immortalized hematopoietic progenitor cells. This novel dual function mouse strain will hence be a valuable tool to rapidly dissect the function of specific genes in leukocyte physiology.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here